Peter S. Sack
Thanks, Tripp. Good morning, everyone. During the second quarter, we continue to demonstrate how well positioned we are at Chicago Atlantic BDC. We remain the only BDC focused on and able to lend to cannabis companies together with substrategies targeted in underserved markets, where the more traditional lenders don't provide capital. In the second quarter, we are excited to announce that we executed on our pipeline and funded $39.1 million of new investments of which 3 were to new borrowers. We have been able to support proven operators in strong markets, while retaining diversity of cash flows, low leverage, high amortization and strong collateral coverage. When stacked up against other BDCs, I would like to highlight our relative strengths. Our weighted average yield on debt investments as of June 30 was 16.1% and compared with the average BDC of 11.8% according to recent public BDC research from Ladenburg Thalmann. Our debt investments are all senior secured compared with other BDCs, who have an average of 18% exposure to second lien subordinated debt or equity. The weighted average secured net leverage for our portfolio companies is 1.9x and interest coverage ratio of 3.2x. The portfolio is underlevered with only $5 million of debt as of the quarter end compared with the BDC average of 1.1x. Assuming full utilization of our $100 million credit facility during the year, we would still be well below industry averages. And we have no non-accruals compared with an industry average of 3.8% of costs. Today, we announced a $0.34 dividend, marking the fourth consecutive quarter at that rate. That brings us to a total of $1.36 in dividends declared over that period. As we scale the platform, we intend to grow this component of our return to shareholders. We have navigated the choppy equity in credit markets during the past 6 months and expect that as we continue to execute on portfolio growth, our shareholders will be the beneficiary of improved total returns as well. With all the news around rescheduling the past few weeks, it's worth reiterating how we continue to approach the cannabis market. Rescheduling would dramatically increase the cash flow after taxes for our borrowers. In the short term, that would translate to higher equity valuations of both public and private cannabis companies. There would likely be increased M&A activity and higher capital expenditure activity driven by the higher free cash flow, leading to greater opportunity for our platform. In the medium and long term, there's still lingering uncertainty that we continue to limit investment until federal regulators put in place a regulatory framework for cannabis as a Schedule III substance. This continued ambiguity will continue to create challenges for U.S. public listings and access to debt markets for cannabis operators. At Chicago Atlantic, we have always underwritten the regulatory status quo. We are not deploying capital based on rescheduling happening or federal legalization. We assume that the environment remains unchanged and underwrite our investments based on cash flow and collateral profiles that exist today. We have a niche strategy with limited lending competition, generating yields above our BDC peers. We believe that with specialization and focus, we can better manage risk as well. This is a potent combination and unique strategy that positions us well for both the near and long term. Tom, why don't you take it from here?